Literature DB >> 2902381

Envelope cross-reactivity in Western blot for HIV-1 and HIV-2 may not indicate dual infection.

R S Tedder1, T O'Connor, A Hughes, H N'jie, T Corrah, H Whittle.   

Abstract

Serological identification of infection with human immunodeficiency virus types 1 and 2 (HIV-1 and HIV-2) by western blot alone may not be sufficient to diagnose dual infection. Extensive cross-reactions (eg, to envelope glycoprotein antibody) are seen on heterologous western blots. The use of other techniques, in this case competitive enzyme-linked immunosorbent assays, indicates that blot patterns previously thought to demonstrate simultaneous dual infections should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902381     DOI: 10.1016/s0140-6736(88)92598-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  No evidence of HIV-2 infection in subjects at risk for AIDS living in north-east Italy.

Authors:  A Del Mistro; A De Rossi; E Francavilla; M T Sartori; L Chieco-Bianchi
Journal:  Eur J Epidemiol       Date:  1991-11       Impact factor: 8.082

2.  Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.

Authors:  B Böttiger; A Karlsson; P A Andreasson; A Nauclér; C M Costa; E Norrby; G Biberfeld
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

3.  Comparison of cervicovaginal humoral immunity in clinically asymptomatic (CDC A1 and A2 category) patients with HIV-1 and HIV-2 infection.

Authors:  L Bélec; C Tévi-Bénissan; T Dupré; A S Mohamed; T Prazuck; J Gilquin; J M Kanga; J Pillot
Journal:  J Clin Immunol       Date:  1996-01       Impact factor: 8.317

4.  Immunoprecipitation of human immunodeficiency virus type 2 glycoproteins by sera positive for human immunodeficiency virus type 1.

Authors:  R T Espejo; P Uribe
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

5.  Mapping the anatomy of the immunodominant domain of the human immunodeficiency virus gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy.

Authors:  M B Oldstone; A Tishon; H Lewicki; H J Dyson; V A Feher; N Assa-Munt; P E Wright
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Localization of immunogenic domains in the human immunodeficiency virus type 2 envelope.

Authors:  M L Huang; M Essex; T H Lee
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

7.  Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades.

Authors:  A Bertoletti; F Cham; S McAdam; T Rostron; S Rowland-Jones; S Sabally; T Corrah; K Ariyoshi; H Whittle
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Current antibody-based immunoassay algorithm failed to confirm three late-stage AIDS cases in China: case report.

Authors:  Yan Li; Jin-Kou Zhao; Ming Wang; Zhi-Gang Han; Wei-Ping Cai; Bo-Jian Zheng; Hui-Fang Xu
Journal:  Virol J       Date:  2010-03-15       Impact factor: 4.099

9.  Fine serotyping of human immunodeficiency virus serotype 1 (HIV-1) and HIV-2 infections by using synthetic oligopeptides representing an immunodominant domain of HIV-1 and HIV-2/simian immunodeficiency virus.

Authors:  A Baillou; B Janvier; G Leonard; F Denis; A Goudeau; F Barin
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

10.  A seroepidemiological study of human immunodeficiency virus infection in northeast Zaire.

Authors:  M C Bernal; M I Galán; M D Ocete; A Leyva; F García; J García-Valdecasas; M C Maroto; G Piédrola
Journal:  Infection       Date:  1994 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.